Lou Schizas

Has consolidated a number of claims in northern Québec. Seems to be building a bit of the base. Results of 40 diamond drill holes will be coming out soon. Need to see volume.

Has lagged while gold stocks have been going up. In a downtrend and it would wait for it to establish an upside trend.

India has only 44% of domestic energy to meet their needs. They want to develop domestic sources. Have about 2000 km² under license. Low liquidity on trading.

Has been some improvement in the fundamentals. 2nd quarter revenues were 3.9 million which is a 247% increase of revenue over the previous quarter. Continuing to lose money. A huge risk.

Up trend has been broken. If it brakes below $8.50 the next level of support is 8.75. Could retest.

Up 194% year-to-date. Average daily volume is only 7900 shares. A liquidity and small market cap issue indicate a high risk profile. Getting higher margins on their sales and rentals.

Finished the first phase of an acquisition of another oilfield. Graph shows support to the upside. Has come off the high's which could be a signal for an exit. Not a lot of revenue.

Have recently announced deals with Hewlett-Packard, Pitney Bowes and a Singapore Telecom. Risky. Very low liquidity. Competitive business.

Highly speculative. A very high number of shares outstanding. Trading below its 50/200 day moving average. Struggling to hold on to its current level. Have had 10 quarters of losses.

Sold their major producing assets and basically there is no more value.

Design, manufacture and distribute the heart saver Ventricular Device. Just split the stock 7 for 1 so the stock moved out. Very thin volume. It needs to break to the up side. Has gone through a lot of troubles. Needs to get significant sales.

Growth has been fed by picking up assets that others didn't want or couldn't hold. Can they continue on this path? Thinks the space has gotten somewhat consolidated. Has been moving sideways.

Has a higher volume compared to Kelman or Acis. The five-year average operating margin is 24%. Looks like it's moving sideways. Has had 10 consecutive quarters of positive earnings but starting to get a little flat.

The five-year average operating margin is a minus 4%.

Looked like it was going to break out of a 200-day moving average but fell back. Did a special warrant financing in October for sales/marketing of Pennsaid. FDA approval has been pending for a long time. Caution.